A Pilot Study on Proteomic Predictors of Mortality in Stable COPD
Proteomic predictors of mortality in COPD and their connection to respiratory, cardiovascular, and cancer-related deaths
Can Proteomic Predictors of Mortality Help Forecast Outcomes in Stable COPD?
Most of the long-term deaths are attributable to respiratory causes, with lower percentages attributed to cardiovascular/cerebrovascular events or cancer.
It is worth nothing that a trend toward better prognoses (disease progression, exacerbations, and mortality) has been observed in the last few years.
This phenomenon may be due to recent changes in treatment and involves the need for new studies on the current predictors of mortality.
Studying proteomic predictors of mortality in COPD to improve survival prognosis
Therefore, the objective of this pilot study was to identify proteomic markers and specific multiprotein signatures that could be useful in predicting long-term mortality, identifying the related pathways and contributing to our knowledge on the mechanisms linked to a poor prognosis for COPD patients.
Proteomic predictors of mortality in COPD: Understanding the biological mechanisms involved in future deaths in long-term patients
A proteomic blood signature found in stable COPD patients can help in establishing their long-term (4-year) survival prognosis.
The most important elements for establishing this prognosis are proteins/peptides linked to the hemostatic and inflammatory statuses during the stable phase, as well as different elements of the immune response.
Furthermore, the present results may help us to better understand the biological mechanisms involved in future deaths in long-term patients.
Authors
Cesar Jessé Enríquez-Rodríguez, Carme Casadevall, Rosa Faner, Sergi Pascual-Guardia, Ady Castro-Acosta, José Luis López-Campos, Germán Peces-Barba, Luis Seijo, Oswaldo Antonio Caguana-Vélez, Eduard Monsó, Diego Rodríguez-Chiaradia, Esther Barreiro, Borja G. Cosío, Alvar Agustí, Joaquim Gea and on behalf of the BIOMEPOC Group
Read more details at
Fecha de publicación
Published: 14 August 2024
Categorías asociadas al artículo
Noticias relacionadas
Using AI for COPD Diagnosis, Equity, Guideline Gaps: Alvar Agusti, MD, PhD
AI in COPD diagnosis can support case finding, spirometry interpretation and equity while GOLD 2026 highlights validation and guideline gaps.
Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials
Astegolimab for COPD was evaluated in the ALIENTO and ARNASA trials to assess its efficacy and safety in patients with frequent exacerbations.
Maternal smoking and CC-16: implications for lung development and COPD across the lifespan
Maternal smoking and CC16 are linked to impaired lung development, lung function decline and emphysema progression, increasing lifelong COPD risk.
Concavity of the maximal expiratory flow–volume curve, and incidence of COPD and respiratory symptoms: a population-based cohort study
Expiratory flow-volume curve concavity predicts future respiratory symptoms but shows lower discriminatory accuracy for COPD incidence than FEV1/FVC.
Characterisation of the gut-lung axis microbiome in clinically stable patients with chronic obstructive pulmonary disease
Gut-lung axis microbiome analysis in stable COPD reveals distinct gut and lung microbiomes associated with airflow limitation, exacerbations and ICS use
Body Mass Index-related genetic factors and COPD imaging phenotypes
BMI genetic factors and COPD are associated with decreased emphysema and increased airway wall thickness across quantitative and visual imaging phenotypes
Imagen desarrollada DALL·E, Canva y Diseño gráfico